An independent scientific referenceTaxonomy · Evidence · Context
PSILOCYBIAA monograph for the digital age.
Research edition Accounts distinguish source checks from human review. Research coverage is incomplete. Read our standards

01First description

Aeruginascin was described from Inocybe aeruginascens rather than from a Psilocybe species. Gartz reported an analysis of aeruginascin in fruit bodies of that mushroom in 1989, and Jensen, Gartz and Laatsch reported it in Planta Medica in 2006 as a trimethylammonium analogue of psilocybin from the same host.

Neither paper is available in abstract or full text through the indexes consulted here, and both are cited for the reports their titles describe.

Sources: [gartz-1989-aeruginascin] [jensen-2006-aeruginascin]

02Occurrence in Psilocybe cubensis

Aeruginascin is among the six tryptamines quantified in Psilocybe cubensis fruiting bodies in a 2026 study, so its presence is not confined to the genus it was first described from. That source is cited at abstract level.

Sources: [sharchaton-2026-tryptamine-variability]

03Scope of this record

This record covers chemical identity and the published history of the compound. It does not describe effects, preparation or dose, and nothing here is guidance for use.

04References

  1. Gartz J (1989). Analysis of Aeruginascin in Fruit Bodies of the Mushroom Inocybe aeruginascens. International Journal of Crude Drug Research 27(3), 141-144. DOI: 10.3109/13880208909053954 Source record ↗

    Source class: primary.

    Source verification history
    • metadata: verified · 2026-09-15 · Psilocybia editorial. Verification source

      Bibliographic record retrieved from Crossref. Authors, title, journal, volume, pages and year read directly from that record.

    • doi: verified · 2026-09-15 · Psilocybia editorial. Verification source

      DOI resolved and matched against the Crossref bibliographic record.

    • content: unavailable · 2026-09-15 · Psilocybia editorial. Verification source

      No abstract or full text available through the indexes consulted. Only the bibliographic record and title were inspected, so this source supports the fact of its own report and not any detail within it.

  2. Jensen N; Gartz J; Laatsch H (2006). Aeruginascin, a Trimethylammonium Analogue of Psilocybin from the Hallucinogenic MushroomInocybe aeruginascens. Planta Medica 72(07), 665-666. DOI: 10.1055/s-2006-931576 Source record ↗

    Source class: primary.

    Source verification history
    • metadata: verified · 2026-09-15 · Psilocybia editorial. Verification source

      Bibliographic record retrieved from Crossref. Authors, title, journal, volume, pages and year read directly from that record.

    • doi: verified · 2026-09-15 · Psilocybia editorial. Verification source

      DOI resolved and matched against the Crossref bibliographic record.

    • content: unavailable · 2026-09-15 · Psilocybia editorial. Verification source

      No abstract or full text available through the indexes consulted. Only the bibliographic record and title were inspected, so this source supports the fact of its own report and not any detail within it.

  3. Sharchaton A; Parsha S; Azerrad S; Dekel Y; Rabah N; Páleníček T; Kurzbaum E (2026). Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions. Journal of Fungi 12(7), 486. DOI: 10.3390/jof12070486 Source record ↗

    Source class: primary.

    Source verification history
    • metadata: verified · 2026-09-15 · Psilocybia editorial. Verification source

      Bibliographic record retrieved from Crossref. Authors, title, journal, volume, pages and year read directly from that record.

    • doi: verified · 2026-09-15 · Psilocybia editorial. Verification source

      DOI resolved and matched against the Crossref bibliographic record.

    • content: verified · 2026-09-15 · Psilocybia editorial. Verification source

      Abstract inspected via Europe PMC. Full text was not retrieved; claims drawn from this source are scoped to the abstract.